Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/176988
Title: Evaluation of the Spanish population coverage of a prospective HLA haplobank of induced pluripotent stem cells
Author: Álvarez Palomo, Belén
García Martínez, Iris
Gayoso, Jorge
Raya Chamorro, Ángel
Veiga, Anna
Abad, María Lluisa
Eiras, Adolfo
Guzmán Fulgencio, María
Luis Hidalgo, Mar
Eguizábal, Cristina
Santos, Silvia
Balas, Antonio
Alenda, Raquel
Sánchez Gordo, Francisco
Ponce Verdugo, Laura
Villa, Juliana
Carreras, Enric
Vidal, Francisco
Madrigal, Alejandro
Herrero, María José
Rudilla, Francesc
Querol Giner, Sergi
Keywords: Cèl·lules mare
Cordó umbilical
Stem cells
Umbilical cord
Issue Date: 13-Apr-2021
Publisher: Springer Nature
Abstract: Background: iPSC (induced pluripotent stem cells) banks of iPSC lines with homozygous HLA (human leukocyte antigen) haplotypes (haplobanks) are proposed as an affordable and off-the-shelf approach to allogeneic transplantation of iPSC derived cell therapies. Cord blood banks offer an extensive source of HLA-typed cells suitable for reprogramming to iPSC. Several initiatives worldwide have been undertaken to create national and international iPSC haplobanks that match a significant part of a population. Methods: To create an iPSC haplobank that serves the Spanish population (IPS-PANIA), we have searched the Spanish Bone Marrow Donor Registry (REDMO) to identify the most frequently estimated haplotypes. From the top ten donors identified, we estimated the population coverage using the criteria of zero mismatches in HLA-A, HLA-B, and HLA-DRB1 with different stringencies: high resolution, low resolution, and beneficial mismatch. Results: We have calculated that ten cord blood units from homozygous donors stored at the Spanish cord blood banks can provide HLA-A, HLA-B, and HLA-DRB1 matching for 28.23% of the population. Conclusion: We confirm the feasibility of using banked cord blood units to create an iPSC haplobank that will cover a significant percentage of the Spanish and international population for future advanced therapy replacement strategies.
Note: Reproducció del document publicat a: https://doi.org/10.1186/s13287-021-02301-0
It is part of: Stem Cell Research & Therapy, 2021, vol. 12
URI: http://hdl.handle.net/2445/176988
Related resource: https://doi.org/10.1186/s13287-021-02301-0
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
s13287-021-02301-0.pdf2.27 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons